Longevity — Page 7 of 7 | Synptide Learn

81 articles in Longevity · page 7 of 7

The framework that organizes modern aging science, in plain language: nine hallmarks in 2013, twelve by 2023, and what changed.

Grip strength predicts mortality and older adults need more protein per meal. What the evidence shows about the muscle-lifespan link.

Fisetin is a plant flavonoid studied as a senolytic, riding mostly on preclinical promise. What the early human data does and does not show.

In a 140,000-person study, lower grip strength predicted death better than systolic blood pressure. Why the marker works so well.

Two popular ways to raise NAD+. Both move the biomarker, and neither has a head-to-head human trial to crown a winner yet.

Precursors reliably raise blood NAD+, but the healthspan benefits people buy them for remain largely unproven in humans.

A cheap diabetes drug with tantalizing longevity signals, still awaiting the trial that could settle it. What TAME would prove.

Senolytics extended lifespan in old mice by 36%. In humans: four small pilots and one randomized trial that missed its primary endpoint.

The most credible pharmacological longevity candidate in mice, and why human lifespan evidence for it still does not exist.